Zimmer Biomet Holdings, Inc. (ZBH)

$108.4

-0.87

(-0.8%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $108.31
    $109.45
    $108.40
    downward going graph

    0.08%

    Downside

    Day's Volatility :1.04%

    Upside

    0.96%

    downward going graph
  • $101.47
    $133.90
    $108.40
    downward going graph

    6.39%

    Downside

    52 Weeks Volatility :24.22%

    Upside

    19.04%

    downward going graph

Returns

PeriodZimmer Biomet Holdings, Inc.Sector (Health Care)S&P500
3 Months
-4.43%
-6.9%
6.8%
6 Months
-9.16%
-1.7%
12.1%
1 Year
-4.77%
10.4%
30.6%
3 Years
-16.76%
8.8%
27.0%

Highlights

Market Capitalization
21.8B
Book Value
$62.00
Dividend Share
0.96
Dividend Yield
0.88%
Earnings Per Share (EPS)
5.24
PE Ratio
20.85
PEG Ratio
1.43
Wall Street Target Price
124.92
Profit Margin
14.27%
Operating Margin TTM
18.0%
Return On Assets TTM
4.61%
Return On Equity TTM
8.71%
Revenue TTM
7.6B
Revenue Per Share TTM
37.01
Quarterly Revenue Growth YOY
4.0%
Gross Profit TTM
4.9B
EBITDA
2.6B
Diluted Eps TTM
5.24
Quarterly Earnings Growth YOY
0.6
EPS Estimate Current Year
7.98
EPS Estimate Next Year
8.58
EPS Estimate Current Quarter
1.73
EPS Estimate Next Quarter
2.27

Analyst Recommendation

Hold
    37%Buy
    56%Hold
    6%Sell
Based on 32 Wall street analysts offering stock ratings for Zimmer Biomet Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
18
18
18
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 15.24%

Current $108.40
Target $124.92

Company Financials

FY18Y/Y Change
Revenue
7.9B
↑ 1.39%
Net Income
-379.2M
↓ 120.61%
Net Profit Margin
-4.78%
↓ 28.29%
FY19Y/Y Change
Revenue
8.0B
↑ 0.62%
Net Income
1.1B
↓ 398.42%
Net Profit Margin
14.18%
↑ 18.96%
FY20Y/Y Change
Revenue
7.0B
↓ 12.0%
Net Income
-137.4M
↓ 112.14%
Net Profit Margin
-1.96%
↓ 16.14%
FY21Y/Y Change
Revenue
6.8B
↓ 2.81%
Net Income
401.6M
↓ 392.29%
Net Profit Margin
5.88%
↑ 7.84%
FY22Y/Y Change
Revenue
6.9B
↑ 1.65%
Net Income
231.4M
↓ 42.38%
Net Profit Margin
3.33%
↓ 2.55%
FY23Y/Y Change
Revenue
7.4B
↑ 6.55%
Net Income
1.0B
↑ 342.52%
Net Profit Margin
13.85%
↑ 10.52%
Q2 FY23Q/Q Change
Revenue
1.9B
↑ 2.11%
Net Income
209.6M
↓ 9.85%
Net Profit Margin
11.21%
↓ 1.49%
Q3 FY23Q/Q Change
Revenue
1.8B
↓ 6.2%
Net Income
162.7M
↓ 22.38%
Net Profit Margin
9.28%
↓ 1.93%
Q4 FY23Q/Q Change
Revenue
1.9B
↑ 10.64%
Net Income
419.2M
↑ 157.65%
Net Profit Margin
21.61%
↑ 12.33%
Q1 FY24Q/Q Change
Revenue
1.9B
↓ 2.62%
Net Income
172.4M
↓ 58.87%
Net Profit Margin
9.13%
↓ 12.48%
Q2 FY24Q/Q Change
Revenue
1.9B
↑ 2.79%
Net Income
242.8M
↑ 40.84%
Net Profit Margin
12.5%
↑ 3.37%
Q3 FY24Q/Q Change
Revenue
1.8B
↓ 6.07%
Net Income
249.2M
↑ 2.64%
Net Profit Margin
13.66%
↑ 1.16%
FY18Y/Y Change
Total Assets
24.1B
↓ 8.58%
Total Liabilities
12.9B
↓ 12.19%
FY19Y/Y Change
Total Assets
24.6B
↑ 2.12%
Total Liabilities
12.2B
↓ 4.71%
FY20Y/Y Change
Total Assets
24.4B
↓ 0.9%
Total Liabilities
12.2B
↓ 0.23%
FY21Y/Y Change
Total Assets
23.5B
↓ 3.94%
Total Liabilities
10.8B
↓ 11.69%
FY22Y/Y Change
Total Assets
21.1B
↓ 10.19%
Total Liabilities
9.0B
↓ 16.23%
FY23Y/Y Change
Total Assets
21.5B
↑ 2.05%
Total Liabilities
9.0B
↓ 0.34%
Q2 FY23Q/Q Change
Total Assets
21.3B
↑ 0.24%
Total Liabilities
8.9B
↓ 1.87%
Q3 FY23Q/Q Change
Total Assets
21.2B
↓ 0.36%
Total Liabilities
8.7B
↓ 2.43%
Q4 FY23Q/Q Change
Total Assets
21.5B
↑ 1.32%
Total Liabilities
9.0B
↑ 3.56%
Q1 FY24Q/Q Change
Total Assets
21.5B
↓ 0.21%
Total Liabilities
8.8B
↓ 1.8%
Q2 FY24Q/Q Change
Total Assets
21.5B
↑ 0.32%
Total Liabilities
8.8B
↓ 0.86%
Q3 FY24Q/Q Change
Total Assets
21.7B
↑ 0.93%
Total Liabilities
9.3B
↑ 6.46%
FY18Y/Y Change
Operating Cash Flow
1.7B
↑ 10.43%
Investing Cash Flow
-416.6M
↓ 18.44%
Financing Cash Flow
-1.3B
↑ 7.58%
FY19Y/Y Change
Operating Cash Flow
1.6B
↓ 9.25%
Investing Cash Flow
-729.3M
↑ 75.06%
Financing Cash Flow
-779.9M
↓ 40.11%
FY20Y/Y Change
Operating Cash Flow
1.2B
↓ 24.04%
Investing Cash Flow
-613.8M
↓ 15.84%
Financing Cash Flow
-421.8M
↓ 45.92%
FY21Y/Y Change
Operating Cash Flow
1.5B
↑ 24.47%
Investing Cash Flow
-503.6M
↓ 17.95%
Financing Cash Flow
-1.3B
↑ 209.63%
FY22Y/Y Change
Operating Cash Flow
1.3B
↓ 14.31%
Investing Cash Flow
-529.2M
↑ 5.08%
Financing Cash Flow
-843.8M
↓ 35.39%
Q2 FY23Q/Q Change
Operating Cash Flow
347.9M
↑ 13.06%
Investing Cash Flow
-392.5M
↑ 162.72%
Financing Cash Flow
-109.4M
↓ 47.07%
Q3 FY23Q/Q Change
Operating Cash Flow
337.6M
↓ 2.96%
Investing Cash Flow
-558.1M
↑ 42.19%
Financing Cash Flow
-196.0M
↑ 79.16%

Technicals Summary

Sell

Neutral

Buy

Zimmer Biomet Holdings, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc.
4.81%
-9.16%
-4.77%
-16.76%
-24.63%
Stryker Corporation
Stryker Corporation
5.37%
16.31%
32.68%
49.88%
93.53%
Boston Scientific Corp.
Boston Scientific Corp.
3.97%
21.4%
65.07%
124.82%
118.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.65%
-21.98%
4.95%
-38.71%
-12.32%
Abbott Laboratories
Abbott Laboratories
0.98%
11.87%
14.18%
-6.39%
40.03%
Medtronic Plc
Medtronic Plc
-7.0%
-1.19%
8.13%
-27.5%
-23.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc.
20.85
20.85
1.43
7.98
0.09
0.05
0.01
62.0
Stryker Corporation
Stryker Corporation
41.34
41.34
2.69
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
74.52
74.52
1.64
2.46
0.09
0.05
NA
14.05
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.17
27.17
6.38
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.56
35.56
2.25
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc.
Hold
$21.8B
-24.63%
20.85
14.27%
Stryker Corporation
Stryker Corporation
Buy
$147.0B
93.53%
41.34
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$132.9B
118.64%
74.52
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.5B
-12.32%
27.17
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$203.2B
40.03%
35.56
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-23.53%
29.55
12.06%

Insights on Zimmer Biomet Holdings, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.94B → 1.82B (in $), with an average decrease of 6.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 172.4M → 249.2M (in $), with an average increase of 15.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 69.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 141.6%

Institutional Holdings

  • Vanguard Group Inc

    11.70%

  • Dodge & Cox

    8.58%

  • BlackRock Inc

    8.46%

  • T. Rowe Price Associates, Inc.

    6.28%

  • State Street Corp

    4.63%

  • American Century Companies Inc

    3.29%

Corporate Announcements

  • Zimmer Biomet Holdings, Inc. Dividends March,2024

    In the quarter ending March,2024. Zimmer Biomet Holdings, Inc. has declared dividend of $0.24

    Read More

Company Information

zimmer biomet is the world’s most trusted brand for personalized bone and joint healthcare solutions. we help people discover and achieve exceptional outcomes. as a leading innovator in musculoskeletal healthcare, we offer a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. every day, we focus on improving musculoskeletal healthcare. it’s all we do. it’s all we’ve ever done. for nearly 90 years, zimmer biomet has helped people progress beyond their pain and limitations. because it’s not just what we make, it’s what we make possible. zimmer biomet serves healthcare professionals and their patients globally. our worldwide headquarters is in warsaw, indiana, usa.

Organization
Zimmer Biomet Holdings, Inc.
Employees
18000
CEO
Mr. Ivan Tornos
Industry
Health Technology

FAQs